HyTK基因转移联合ganciclovir对瘢痕成纤维细胞的体外杀伤作用

增生性瘢痕和瘢痕疙瘩的过度增生主要是由于高度增生活性的成纤维细胞的数量异常增多及细胞外基质合成增加所致．用逆转录病毒载体介导单纯疱疹病毒胸苷激酶基因（ＨＳＶｔｋ）的转移,随后应用药物９－（１,３－二羟基－丙氧基－甲基）鸟嘌呤（ｇａｎｃｉｃｌｏｖｉｒ,ＧＣＶ）可选择性地杀死增生细胞．采用组织块贴壁法在体外原代培养成功增生性瘢痕病人的成纤维细胞（ＦＢ）．重组逆转录病毒ＧＴＫ转染ＦＢ细胞后,用ｈｙｇｒｏｍｙｃｉｎＢ筛选出阳性细胞克隆（ＦＢ／ＧＴＫ）,经ＰＣＲ方法检测证明ＨｙＴＫ基因已成功地导入ＦＢ中,但不含可复制的辅助病毒．分别用不同浓度的ＧＣＶ作用于ＦＢ／ＧＴＫ及ＦＢ,光镜下观察不同时间后细胞形态变化及ＭＴＴ法检测细胞活性．结果表明,ＧＣＶ浓度大于０．１μｍｏｌ／Ｌ时即对ＦＢ／ＧＴＫ有显著的杀伤作用,且具有强有力的“旁观者效应”     

细胞松驰素B促微丝解聚对DNA合成的作用

利用微丝（ｍｉｃｒｏｆｉｌａｍｅｎｔ,ＭＦ）解聚药物细胞松驰素Ｂ（ｃｙｔｏｃｈａｌａｓｉｎＢ,ＣＢ）处理Ｇ_０期小鼠Ｃ_３Ｈ_（１０）Ｔ_（１／２）成纤维细胞,对Ｇ_０至Ｓ期ＤＮＡ合成,胸腺嘧啶核苷激酶（ｔｈｙｍｉｄｉｎｅｋｉｎａｓｅ,ＴＫ）活性、ＴＫ基因表达、钙调素（ｃａｌｍｏｄｕｌｉｎ,ＣａＭ）水平和一些细胞周期早期基因的表达进行了观察,Ｇ_０期细胞经３ｍｇ／ＬＣＢ处理２ｈ,促ＭＦ解聚增强了血清对Ｓ期细胞ＴＫ活性、ＴＫ基因表达和ＤＮＡ合成的刺激作用,并促进细胞提前进入Ｓ期．血清刺激Ｇ_０期细胞进入晚Ｇ_１期和Ｓ期时,ＣａＭ水平明显升高,而ＣＢ预处理则使ＣａＭ含量进一步增加,特别是ＣＢ处理促使Ｓ期ＣａＭ增加向核内转移．ＣＢ处理明显增强血清对ｃ－ｊｕｎ、ｃ－ｆｏｓ和ｃ－ｍｙｃ基因表达的刺激作用,而ＰＫＣ抑制剂Ｈ_７则抑制ＣＢ处理对这些基因转录的刺激作用,说明ＣＢ使Ｇ_０期细胞ＭＦ解聚刺激ｃ－ｊｕｎ、ｃ－ｆｏｓ和ｃ－ｍｙｃ的转录活性与ＰＫＣ的作用有关．结果表明Ｇ_０至Ｓ期早期ＭＦ的重组可促进细胞进入Ｓ期,增强ＤＮＡ合成．     

腺病毒载体介导的肝癌细胞专一性自杀基因表达

构建由肝癌细胞专一的ａｆｐ基因表达调节元件控制自杀基因ＨＳＶ－ｔｋ的穿梭质粒,将它与缺陷型腺病毒载体重组,得到ＡｄｒＡＦＰＴＫ病毒。经ＰＣＲ及Ｓｏｕｔｈｅｒｎ杂交等证实它们含ａｆｐ元件和ｔｋ基因。空斑形成试验表明病毒效价达１×１０１５ｐｆｕ／Ｌ。同时构建由ＣＭＶ启动子控制ｔｋ基因的类似载体作为对照。将这两个重组腺病毒分别感染ＡＦＰ阳性（ＨｅｐＧ２）或阴性（ＨｅＬａ,ＢＲＬ－３Ａ）细胞株（ｍ．ｏ．ｉ．＝１００）,以丙氧鸟苷（ｇａｎｃｉｃｌｏｖｉｒ,ＧＣＶ）处理后,用ＭＴＴ法测定杀伤细胞的效应。结果,ＡｄＣＭＶＴＫ感染这三种细胞后,ＧＣＶ半杀伤浓度分别为１．３、２、＜１μｍｏｌ／Ｌ;但是,ＡｄｒＡＦＰＴＫ感染的ＨｅＬａ和ＢＲＬ－３Ａ细胞的ＧＣＶ半杀伤浓度都＞１０００μｍｏｌ／Ｌ,而对ＨｅｐＧ２细胞只有＜１μｍｏｌ／Ｌ,表现出极高的细胞专一性。重组腺病毒ＡｄｒＡＦＰＴＫ可望用于肝癌的专一性基因治疗     

重组逆转录病毒载体GTK的构建及HyTK基因转移的研究

用逆转录病毒载体将单纯疱疹病毒胸苷激酶基因（ＨＳＶｔｋ）导入恶性肿瘤细胞,随后可应用药物９－（１,３－二羟基－丙氧基－甲基）鸟嘌呤（ｇａｎｃｉｃｌｏｖｉｒ,ＧＣＶ）选择性地杀死肿瘤细胞．将ＨｙＴＫ基因替换逆转录病毒载体ＧｌＮａ中的ｎｅｏ基因,构建成重组逆转录病毒载体ＧＴＫ,转染混合包装细胞（双噬性ＰＡ３１７细胞和单噬性ＧＰ＋Ｅ－８６细胞）,通过“乒乓效应”获得高滴度重组病毒．用该重组病毒转染小鼠恶性黑色素瘤细胞系Ｂ１６细胞,用ｈｙｇｒｏｍｙｃｉｎＢ筛选出阳性细胞克隆（ＨｙＴＫ＋）,经ＰＣＲ方法检测证明ＨｙＴＫ基因已成功地导入肿瘤细胞中,且不含可复制的辅助病毒．分别用不同浓度的ＧＣＶ作用于ＨｙＴＫ－及ＨｙＴＫ＋的Ｂ１６细胞,光镜下观察２４ｈ和４８ｈ后细胞形态及进行活细胞计数．结果表明,ＧＣＶ浓度大于０．１μｍｏｌ／Ｌ时即对Ｂ１６／ＨｙＴＫ＋细胞有显著的杀伤作用     

细胞松弛素B促微丝解聚对DNA合成的作用

利用微丝（ＭＦ）解聚药物细胞松弛素Ｂ（ＣＢ）处理Ｇ０期小鼠Ｃ３Ｈ１０Ｔ１／２成纤维细胞,对Ｇ０至Ｓ期ＤＮＡ合成,胸腺嘧啶核苷激酶（ＴＫ）活性、ＴＫ基因表达、钙调素（ＣａＭ）水平和一些细胞周期早期基因的表达进行了观察。Ｇ０期细胞经３ｍｇ／ＬＣＢ处理２ｈ,促ＭＦ解聚增强了血清对Ｓ期细胞ＴＫ活性、ＴＫ基因表达和ＤＮＡ合成的刺激作用,并促进细胞提前进入Ｓ期。血清刺激Ｇ０期细胞进入晚Ｇ１期和Ｓ期时,ＣａＭ     

HSV—TK／GCV系统杀伤肝癌细胞的在体研究

目的和方法：将可产生含有ＨＳＶＴＫ基因逆转录病毒的包装细胞与ＢＥＬ７４０２肝癌细胞混合后,接种于裸鼠皮下,复制肝癌模型。确定ＨＳＶＴＫ基因转移后,给予动物注射ＧＣＶ,观察ＨＳＶＴＫ／ＧＣＶ系统基因治疗实验性肝癌的在体疗效。结果：在体条件下,逆转录病毒可将ＨＳＶＴＫ基因部分转导至肝癌细胞;ＧＣＶ作用后,ＴＫ＋中瘤细胞的生长受到明显抑制;电镜观察发现,ＧＣＶ杀伤ＴＫ＋肿瘤细胞的作用主要体现在细胞核;虽然组化染色分析表明ＴＫ基因转移效率只有１０％～３０％,但测量肿瘤体积显示ＨＳＶＴＫ／ＧＣＶ系统杀伤肝癌细胞的效果依然明显,故其作用机制可与“旁观者效应”有关。结论：ＨＳＶＴＫ／ＧＣＶ“自杀”基因系统有可能成为基因治疗肝癌的有效方法     

胸苷激酶基因治疗胃癌的体外实验

将单纯疱疹病毒胸苷激酶基因（ＨＳＶ－ｔｋ）导入恶性肿瘤细胞,随后可应用药物丙氧鸟苷（ｇａｎｃｉｃｌｏｖｉｒ, ＧＣＶ）选择性杀死肿瘤细胞．构建了含胸苷激酶与潮霉素磷酸转移酶（ｈｐｈ）融和基因（ＨｙｔＫ）的真核表达载体ＬＸｐｓｐ－ＨｙｔＫ．以脂质体（ｌｉｐｏｆｅｃｔｉｎ）为介导,将这种质粒与仅含潮霉素Ｂ基因的质粒ＬＸＳＨ 分别转染胃癌细胞系ＢＧＣ－８２３,用６０ Ｕ／ｍ ｌ潮霉素Ｂ进行筛选,得到了可稳定传代的阳性克隆,分别命名为ＢＧＣ－ＨｙｔＫ 和ＢＧＣ－Ｈｙ．三种细胞的生长曲线无明显差别．用不同浓度的ＧＣＶ 分别作用于ＢＧＣ－ＨｙｔＫ, ＢＧＣ－Ｈｙ 及ＢＧＣ－８２３,０．０２～２００ μｇ／ｍ ｌ 的ＧＣＶ 对ＢＧＣ－ＨｙｔＫ 细胞有明显的杀伤作用（ＩＣ５０＝ ０．０２ μｇ／ｍ ｌ）,而对另外两种细胞几乎无毒性作用（ＩＣ５０＞ ２００μｇ／ｍ ｌ）．２０ μｇ／ｍ ｌＧＣＶ 作用９６ ｈ 后,仅存在２０％ 的ＢＧＣ－ＨｙｔＫ 就可使周围的大部分ＨＳＶ－ｔｋ－ 的肿瘤细胞死亡,说明存在较显著的“旁观者效应”     

抗菌肽与碱性成纤维细胞生长因子基因的融合及其在酵母中的表达

从重组质粒ｒＢＳ上切下柞蚕抗菌肽Ｄ基因片段,切去终止密码后连接到重组穿梭质粒ｐＶＴ－ＧＦ上碱上成纤维细胞生长因子ｃＤＮＡ的５′端,使密码框正确排列,构建成融合 组质粒ｐＶＴ－ＣＤＧＦ,转化到酵母中进行表达。转化子酵母蛋白粗提物用Ｅ．ｃｏｌｉＫ１２Ｄ３１作指示菌进行抑菌圈测试,初步检出具有换菌活性,用ＥＬＩＳＡ检测证明其具有碱性成纤细胞生长因子的抗原性。     

抗菌肽与碱性成纤维细胞生长因子基因的融合及其在酵母中的表达

从重组质粒ｒＢＳ上切下柞蚕抗菌肽Ｄ基因片段,切去终止密码后连接到重组穿梭质粒ｐＶＴ－ＧＦ上碱性成纤维细胞生长因子ｃＤＮＡ的５′端,使密码框正确排列,构建成融合基因重组质粒ｐＶＴ－ＣＤＧＦ,转化到酵母中进行表达。转化子酵母蛋白粗提物用Ｅ．ｃｏｌｉＫ１２Ｄ３１作指示菌进行抑菌圈测试,初步检出具有抑菌活性,用ＥＬＩＳＡ检测证明其具有碱性成纤维细胞生长因子的抗原性。     

MTT法测定眼镜蛇毒细胞毒素的抗癌活性

目的测定眼镜蛇毒细胞毒素（Ｃｏｂｒａｖｅｎｏｍｃｙｔｏｔｏｘｉｎ,ＣＶ－ＣＴＸ）对体外培养的人癌细胞的杀伤作用。方法溴化二苯四偶氮盐（ＭＴＴ）比色法。结果ＣＶ－ＣＴＸ对ＳＧＣ－７９０１,Ｂｅｌ－７４０２,Ｋ５６２和Ｕ９３７４种人癌细胞有很强的杀伤作用,量效关系明显,ＩＣ５０分别为４．１０,２．０８,０．２９和０．１７μｇ／ｍｌ。结论ＭＴＴ法检测ＣＶ－ＣＴＸ的抗癌活性,操作简便、快速和准确。     

I型单纯疱疹病毒胸苷激酶真核表达载体的构建及其表达鉴定

为构建单纯疱疹病毒I型胸苷激酶(HSV1TK)的真核表达载体pcDNA3.1-EGFP/HSV1TK,鉴定其在真核细胞中的表达和功能.以pORF-HSV1TK为模板,PCR扩增的目的基因HSV1TK片段与pMD18-T载体相连接构建重组克隆pMD18-T/HSV1TK.再双酶切出HSV1TK片段,插入pcDNA3.1-EGFP多克隆位点,构建pcDNA3.1-EGFP/ HSV1TK真核表达载体并进行酶切、测序鉴定[1].分别用荧光显微镜观察和RT-PCR方法检测脂质体介导pcDNA3.1-EGFP/ HSV1TK在卵巢癌细胞SKOV3的表达;分别用MTT法和光镜检测胸苷激酶/丙氧鸟苷(HSV1TK/GCV)系统对SKOV3体外杀伤作用及旁观者效应.结果表明,重组载体酶切鉴定结果与预期结果一致,基因序列与GenBank上报道的HSV1TK基因序列完全一致.荧光显微镜观察转染后的细胞发出绿色荧光;RT-PCR结果表明HSV1TK基因能在SKOV3内有效表达.MTT和光镜结果显示转染HSV1TK基因的SKOV3细胞,加入前体药物丙氧鸟苷(GCV)处理后对其有明显的杀伤作用和旁观者效应.成功构建的真核表达载体pcDNA3.1-EGFP/ HSV1TK能在SKOV3细胞中稳定表达,且HSV1TK对卵巢癌细胞株SKOV3体外有强大的杀伤作用和旁观者效应.     

Differential ganciclovir-mediated cell killing by glutamine 125 mutants of herpes simplex virus type 1 thymidine kinase

The therapeutic combination of the herpesvirus simplex virus type 1 (HSV-1) thymidine kinase (TK) gene and the prodrug, ganciclovir (GCV), has found great utility for the treatment of many types of cancer. After initial phosphorylation of GCV by HSV-1 TK, cellular kinases generate the toxic GCV-triphosphate metabolite that is incorporated into DNA and eventually leads to tumor cell death. The cellular and pharmacological mechanisms by which metabolites of GCV lead to cell death are still poorly defined. To begin to address these mechanisms, different mutated forms of HSV-1 TK at residue Gln-125 that have distinct substrate properties were expressed in mammalian cell lines. It was found that expression of the Asn-125 HSV-1 TK mutant in two cell lines, NIH3T3 and HCT-116, was equally effective as wild-type HSV-1 TK for metabolism and sensitivity to GCV, bystander effect killing and induction of apoptosis. The major difference between the two enzymes was the lack of deoxypyrimidine metabolism in the Asn-125 TK-expressing cells. In HCT-116 cells expressing the Glu-125 TK mutant, GCV metabolism was greatly attenuated, yet at higher GCV concentrations, cell sensitivity to the drug and bystander effect killing were diminished but still effective. Cell cycle analysis, 4', 6'-diamidine-2'-phenylindoledihydrochloride staining, and caspase 3 activation assays indicated different cell death responses in the Glu-125 TK-expressing cells as compared with the wild-type HSV-1 TK or Asn-125 TK-expressing cells. A mechanistic hypothesis to explain these results based on the differences in GCV-triphosphate metabolite levels is presented.     

Human herpesvirus 8-encoded thymidine kinase and phosphotransferase homologues confer sensitivity to ganciclovir

Human herpesvirus 8 (HHV-8) sensitivity to the nucleoside analog ganciclovir (GCV) suggests the presence of a virally encoded kinase that catalyzes the initial phosphorylation of GCV. Analysis of the HHV-8 genome identified two candidate kinases: proteins encoded by open reading frame (ORF) 21, with homology to the herpesvirus thymidine kinases (TK), and ORF 36, with homology to the herpesvirus phosphotransferases (PT). Experiments presented here show that both ORF 21 and ORF 36 encode GCV kinase activities as demonstrated by GCV phosphorylation and GCV-mediated cell death. In both regards the PT homologue ORF 36 was more active than the TK homologue ORF 21. ORF 21, but not ORF 36, weakly sensitized cells to killing by penciclovir. Neither ORF sensitized cells to killing by (E)-5-(2-bromovinyl)-2'-deoxyuridine.     

健脾化瘀中药提高胞嘧啶脱氨酶/单纯疱疹病毒胸苷激酶基因治疗肝细胞癌的实验研究

目的:观察健脾化瘀中药提高胞嘧啶脱氨酶/单纯疱疹病毒胸苷激酶基因治疗肝细胞癌的作用。方法:脂质体lipofectamine将含有双自杀基因的腺病毒载体pAd-CD/TK导人293细胞,收集病毒上清转染人肝癌细胞BEL7402,MTT法测定BEL7402细胞存活率。裸鼠人肝癌模型转染CD/TK双自杀基因后,给予5-FC500mg/kg,GCV 100mg/kg腹腔注射,同时予健脾化瘀中药960复方灌胃。观察肿瘤生长情况。结果:给予前体药物5-FC和GCV后,CD/TK转染细胞被杀死。并表现出较强的旁观者效应。转染细胞比例达到10%即表现出较强的杀伤作用(P<0.01)。健脾化瘀中药960复方具有提高旁观者效应作用,1.67ml/kg和2.5ml/kg960复方含药血清组细胞存活率显著低于对照组(P<0.01)。转染基因组应用5-FC和GCV治疗后,裸鼠肝癌的生长明显受到抑制(P<0.05),抑瘤率39.42%,单用中药组抑瘤率18.04%,中药与CD/TK 5-FC/GCV联合运用组,较单纯CD/5-FC/HSV-tk/GCV对裸鼠肿瘤模型的生长抑制作用更加明显(P<0.05),抑瘤率55.10%。结伦:腺病毒介导CD/TK自杀基因可有效地杀死人肝癌BEL7402细胞,健脾化瘀中药960复方具有显著提高CD/TK双自杀基因对人肝癌细胞的抑杀作用。     

The role of a HSV thymidine kinase stimulating substance, scopadulciol, in improving the efficacy of cancer gene therapy

BACKGROUND: The most extensively investigated strategy of suicide gene therapy for treatment of cancer is the transfer of the herpes simplex virus thymidine kinase (HSV-TK) gene followed by administration of antiviral prodrugs such as acyclovir (ACV) and ganciclovir (GCV). The choice of the agent that can stimulate HSV-TK enzymatic activity is one of the determinants of the usefulness of this strategy. Previously, we found that a diterpenoid, scopadulciol (SDC), produced a significant increase in the active metabolite of ACV. This suggests that SDC may play a role in the HSV-TK/prodrug administration system. METHODS: The anticancer effect of SDC was evaluated in HSV-TK-expressing (TK+) cancer cells and nude mice bearing TK+ tumors. In vitro and in vivo enzyme assays were performed using TK+ cells and tumors. The phosphorylation of ACV monophosphate (ACV-MP) was measured in TK- cell lysates. The pharmacokinetics of prodrugs was evaluated by calculating area-under-the-concentration-time-curve values. RESULTS: SDC stimulated HSV-TK activity in TK+ cells and tumors, and increased GCV-TP levels, while no effect of SDC was observed on the phosphorylation of ACV-MP to ACV-TP by cellular kinases. The SDC/prodrug combination altered the pharmacokinetics of the prodrugs. In accord with these findings, SDC enhanced significantly the cell-killing activity of prodrugs. The bystander effect was also significantly augmented by the combined treatment of ACV/GCV and SDC. CONCLUSIONS: SDC was shown to be effective in the HSV-TK/prodrug administration system and improved the efficiency of the bystander effect of ACV and GCV. The findings will be considerably valuable with respect to the use of GCV in lower doses and less toxic ACV. This novel strategy of drug combination could provide benefit to HSV-TK/prodrug gene therapy.     

Engineering of a single conserved amino acid residue of herpes simplex virus type 1 thymidine kinase allows a predominant shift from pyrimidine to purine nucleoside phosphorylation

Studies of herpes simplex virus type 1 (HSV-1) thymidine (dThd) kinase (TK) crystal structures show that purine and pyrimidine bases occupy distinct positions in the active site but approximately the same geometric plane. The presence of a bulky side chain, such as tyrosine at position 167, would not be sterically favorable for pyrimidine or pyrimidine nucleoside analogue binding, whereas purine nucleoside analogues would be less affected because they are located further away from the phenylalanine side chain. Site-directed mutagenesis of the conserved Ala-167 and Ala-168 residues in HSV-1 TK resulted in a wide variety of differential affinities and catalytic activities in the presence of the natural substrate dThd and the purine nucleoside analogue drug ganciclovir (GCV), depending on the nature of the amino acid mutation. A168H- and A167F-mutated HSV-1 TK enzymes turned out to have a virtually complete knock-out of dThd kinase activity (at least approximately 4-5 orders of magnitude lower) presumably due to a steric clash between the mutated amino acid and the dThd ring. In contrast, a full preservation of the GCV (and other purine nucleoside analogues) kinase activity was achieved for A168H TK. The enzyme mutants also markedly lost their binding capacity for dThd and showed a substantially diminished feedback inhibition by thymidine 5'-triphosphate. The side chain size at position 168 seems to play a less important role regarding GCV or dThd selectivity than at position 167. Instead, the nitrogen-containing side chains from A168H and A168K seem necessary for efficient ligand discrimination. This explains why A168H-mutated HSV-1 TK fully preserves its GCV kinase activity (Vmax/Km 4-fold higher than wild-type HSV-1 TK), although still showing a severely compromised dThd kinase activity (Vmax/Km 3-4 orders of magnitude lower than wild-type HSV-1 TK).